Literature DB >> 10815374

Tumour-associated macrophages (TAMS): disordered function, immune suppression and progressive tumour growth.

B al-Sarireh1, O Eremin.   

Abstract

Evidence currently available suggests that in established, progressively growing solid tumours, tumour associated macrophages (TAMs) are reprogrammed to induce immune suppression of host defenses in situ, through release of specific cytokines, prostanoids and other humoral mediators. This disordered response, results in the inhibition of effective anti-cancer cell-mediated immune mechanisms. Concurrently, TAMs produce tumour growth promoting factors. The summation of this complex interplay of biological factors results in progressive tumour growth and tumour cell dissemination. A better understanding of these complex inter-relationships should form the basis of novel strategies designed to eradicate tumour cells in man and animals. These various biological aspects and processes are discussed in detail and critically evaluated in this review article.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10815374

Source DB:  PubMed          Journal:  J R Coll Surg Edinb        ISSN: 0035-8835


  32 in total

Review 1.  The macrophage growth factor CSF-1 in mammary gland development and tumor progression.

Authors:  Elaine Y Lin; Valerie Gouon-Evans; Andrew V Nguyen; Jeffrey W Pollard
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-04       Impact factor: 2.673

2.  Measurement of tumour necrosis factor receptors for immune response in colon cancer patients.

Authors:  K Venetsanou; V Kaldis; N Kouzanidis; Ch Papazacharias; J Paraskevopoulos; G Baltopoulos
Journal:  Clin Exp Med       Date:  2011-11-01       Impact factor: 3.984

3.  NCOA1 Directly Targets M-CSF1 Expression to Promote Breast Cancer Metastasis.

Authors:  Li Qin; Ye-Lin Wu; Michael J Toneff; Dabing Li; Lan Liao; Xiuhua Gao; Fiona T Bane; Jean C-Y Tien; Yixiang Xu; Zhen Feng; Zhihui Yang; Yan Xu; Sarah M Theissen; Yi Li; Leonie Young; Jianming Xu
Journal:  Cancer Res       Date:  2014-04-25       Impact factor: 12.701

4.  Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen.

Authors:  Neil L Berinstein; Gregory T Wolf; Paul H Naylor; Lorraine Baltzer; James E Egan; Harvey J Brandwein; Theresa L Whiteside; Lynn C Goldstein; Adel El-Naggar; Cecile Badoual; Wolf-Herve Fridman; J Michael White; John W Hadden
Journal:  Cancer Immunol Immunother       Date:  2011-11-06       Impact factor: 6.968

5.  Tumoristatic effects of anti-CD40 mAb-activated macrophages involve nitric oxide and tumour necrosis factor-alpha.

Authors:  Hillary D Lum; Ilia N Buhtoiarov; Brian E Schmidt; Gideon Berke; Donna M Paulnock; Paul M Sondel; Alexander L Rakhmilevich
Journal:  Immunology       Date:  2006-06       Impact factor: 7.397

Review 6.  Biomarkers and the genetics of early neoplastic lesions.

Authors:  Sudhir Srivastava; William E Grizzle
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

7.  EBV infection determines the immune hallmarks of plasmablastic lymphoma.

Authors:  Pauline Gravelle; Sarah Péricart; Marie Tosolini; Bettina Fabiani; Paul Coppo; Nadia Amara; Alexandra Traverse-Gléhen; Nathalie Van Acker; Pierre Brousset; Jean-Jacques Fournie; Camille Laurent
Journal:  Oncoimmunology       Date:  2018-07-30       Impact factor: 8.110

8.  Progressive growth of a murine T cell lymphoma alters population kinetics and cell viability of macrophages in a tumor-bearing host.

Authors:  Pramod K Gautam; Babu N Maurya; Sanjay Kumar; Praveen Deepak; Sanjay Kumar; Munendra S Tomar; Arbind Acharya
Journal:  Tumour Biol       Date:  2012-12-18

9.  Therapeutic Antibodies Targeting CSF1 Impede Macrophage Recruitment in a Xenograft Model of Tenosynovial Giant Cell Tumor.

Authors:  Hongwei Cheng; Paul W Clarkson; Dongxia Gao; Marina Pacheco; Yuzhuo Wang; Torsten O Nielsen
Journal:  Sarcoma       Date:  2010-10-13

10.  Targeting tumor microenvironment: the key role of immune system.

Authors:  Jaleh Barar
Journal:  Bioimpacts       Date:  2012-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.